Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Mortality risk is associated with disease activity in patients with Sjögren disease: a South Australian retrospective cohort study.

Created on 18 Nov 2026

Authors

Chandra Kirana, Susan E Lester, Sarah Downie Doyle, Maureen Rischmueller

Published in

Rheumatology (Oxford, England). Nov 17, 2026. Epub Nov 17, 2026.

Abstract

To evaluate the overall risk of mortality in Sjögren disease (SjD) and its relationship to baseline systemic disease activity in an Australian population.
This retrospective cohort study included 241 patients fulfilling 2016 ACR-EULAR classification criteria from the South Australian (SA) Sjögren Disease Registry with up to 30 years of follow-up. Baseline data included patient demographics, serology and disease activity (ESSDAI). Analysis included the standardised mortality ratio (SMR) and cox regression.
Patients were predominantly female (217, 89%), with a median age at diagnosis of 58 years. Most had oral (99%) and ocular (97%) dryness, Ro/La autoantibodies (193, 80%) and rheumatoid factor (RF, 142, 61%). ESSDAI scores were grouped into low (<5), n = 121 (50%); moderate (5-13), n = 92 (38%); and high (>13), n = 28 (12%). Mortality was not increased compared to the SA population (SMR 1.18, 95%CI 0.90, 1.54). Patients with high baseline ESSDAI disease activity had a four-fold mortality risk compared to patients with low disease activity (HR 3.9, 95%CI 1.7, 8.7). Moderate to high activity in ESSDAI renal or pulmonary domains, and any activity in the biological domain, contributed to this increased mortality. Rheumatoid factor positivity was independently associated with mortality risk (HR 2.2, 95%CI 1.0, 4.7). Causes of death were cardiovascular, pulmonary, infections, cancer, and kidney disease.
High disease activity at baseline, including moderate to high activity in renal and pulmonary and any activity in biological domain, and positive rheumatoid factor are associated with increased mortality risk in SjD patients, underscoring the systemic impact of this disease.

PMID:
43046607
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement